» Articles » PMID: 19996046

Predictors of Suboptimal Virologic Response to Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus-infected Adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project

Overview
Specialty Pediatrics
Date 2009 Dec 10
PMID 19996046
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the prevalence and biopsychosocial predictors of suboptimal virologic response to highly active antiretroviral therapy (HAART) among human immunodeficiency virus-infected adolescents.

Design: Population-based cohort study.

Setting: Sixteen academic medical centers across 13 cities in the United States.

Participants: One hundred fifty-four human immunodeficiency virus-infected adolescents who presented for at least 2 consecutive visits after initiation of HAART.

Main Outcome Measures: Viral load (plasma concentration of human immunodeficiency virus RNA) and CD4(+) lymphocyte count.

Results: Of the 154 adolescents enrolled in the study, 50 (32.5%) demonstrated early and sustained virologic suppression while receiving HAART. The remaining 104 adolescents (67.5%) had a poor virologic response. Adequate adherence (>50%)-reported by 70.8% of respondents-was associated with 60% reduced odds of suboptimal virologic suppression in a multivariable logistic regression model (adjusted odds ratio = 0.4; 95% confidence interval, 0.2-1.0). Exposure to suboptimal antiretroviral therapy prior to HAART, on the other hand, was associated with more than 2-fold increased odds of suboptimal virologic response (adjusted odds ratio = 2.6; 95% confidence interval, 1.1-5.7).

Conclusions: Fully two-thirds of human immunodeficiency virus-infected adolescents in the current study demonstrated a suboptimal virologic response to HAART. Nonadherence and prior single or dual antiretroviral therapy were associated with subsequent poor virologic responses to HAART. These predictors of HAART failure echo findings in pediatric and adult populations. Given the unique developmental stage of adolescence, age-specific interventions are indicated to address high rates of nonadherence and therapeutic failure.

Citing Articles

Virological failure and associated factors among patients receiving anti-retroviral therapy in Ethiopia: A systematic review and meta-analysis.

Aytenew T, Asferie W, Ejigu N, Birhane B, Tiruneh Y, Kassaw A BMJ Open. 2024; 14(11):e087569.

PMID: 39613423 PMC: 11605831. DOI: 10.1136/bmjopen-2024-087569.


Inflammatory profile of vertically HIV-1 infected adolescents receiving ART in Cameroon: a contribution toward optimal pediatric HIV control strategies.

Kae A, Nanfack A, Ambada G, Santoro M, Takou D, Ngoufack Jagni Semengue E Front Immunol. 2023; 14:1239877.

PMID: 37646023 PMC: 10461471. DOI: 10.3389/fimmu.2023.1239877.


"It must start with me, so it started with me": A qualitative study of Project YES! youth peer mentor implementing experiences supporting adolescents and young adults living with HIV in Ndola, Zambia.

Burke V, Frimpong C, Miti S, Mwansa J, Abrams E, Merrill K PLoS One. 2022; 17(2):e0261948.

PMID: 35113861 PMC: 8812956. DOI: 10.1371/journal.pone.0261948.


Prevalence and Predictors of Virological Failure Among Adults Living with HIV in South Wollo Zone, Northeast Ethiopia: A Retrospective Cohort Study.

Wendie T, Workneh B HIV AIDS (Auckl). 2020; 12:393-402.

PMID: 33061655 PMC: 7519846. DOI: 10.2147/HIV.S266460.


Project YES! Youth Engaging for Success: A randomized controlled trial assessing the impact of a clinic-based peer mentoring program on viral suppression, adherence and internalized stigma among HIV-positive youth (15-24 years) in Ndola, Zambia.

Denison J, Burke V, Miti S, Nonyane B, Frimpong C, Merrill K PLoS One. 2020; 15(4):e0230703.

PMID: 32240186 PMC: 7117673. DOI: 10.1371/journal.pone.0230703.


References
1.
Futterman D . HIV and AIDS in adolescents. Adolesc Med Clin. 2004; 15(2):369-91. DOI: 10.1016/j.admecli.2004.02.009. View

2.
Rosenberg P, Biggar R . Trends in HIV incidence among young adults in the United States. JAMA. 1998; 279(23):1894-9. DOI: 10.1001/jama.279.23.1894. View

3.
Press N, Tyndall M, Wood E, Hogg R, Montaner J . Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2003; 31 Suppl 3:S112-7. DOI: 10.1097/00126334-200212153-00005. View

4.
Florence E, Lundgren J, Dreezen C, Fisher M, Kirk O, Blaxhult A . Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003; 4(3):255-62. DOI: 10.1046/j.1468-1293.2003.00156.x. View

5.
Reisner S, Mimiaga M, Skeer M, Perkovich B, Johnson C, Safren S . A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009; 17(1):14-25. PMC: 3752381. View